Shots:
- The US FDA has granted IND clearance to initiate the P-I trial assessing the safety, tolerability, PK, & anti-tumor activity of Harbour Biomed‘s HBM7004 in advanced solid tumors
- Preclinical studies showed that HBM7004 induced B7H4-dependent intratumoral T-cell activation, strong anti-tumor activity, in vivo stability, & reduced systemic toxicity, while combination with a B7H4x4-1BB BsAb at a low effector-to-target cell ratio demonstrated synergistic efficacy & a potentially favorable therapeutic window
- HBM7004 is a novel B7H4xCD3 bispecific antibody developed using Harbour’s HBICE platform, designed to enhance cancer immunotherapy efficacy & safety while highlighting the platform’s versatile plug-and-play capabilities
Ref: PRnewswire | Image: HarbourBiomed | Press Release
Related News: Harbour BioMed Collaborates with Yantai Lannacheng Biotechnology to Develop Radionuclide Drug Conjugates (RDCs)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
